BioSpace News Archive

Orum Therapeutics, a private biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced the presentation of preclinical data for ORM-6151, a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader for acute myeloid leukemia (AML).

Arima Genomics, Inc., the leader in 3D genomics, today announced a new partnership with Basepair to empower scientists with new options for bioinformatic analysis of 3D genomic data.

OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that the Company received U.S. FDA clearance for its ORAcollect®•Dx saliva collection device for OTC (i.e. direct-to-consumer) use.

Harpoon Therapeutics, Inc. announced that it will present updated interim data from its Phase 1 clinical trial evaluating single-agent HPN217 in relapsed/refractory multiple myeloma in a poster presentation at the 64th American Society of Hematology Annual Meeting and Exposition being held in person in New Orleans, Louisiana and virtually from December 10-13, 2022.

BeiGene, (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced clinical and real-world data accepted at the 64th American Society of Hematology (ASH) Annual Meeting, scheduled for December 10-14, 2022, in New Orleans.

EdiGene, Inc. announced it will present preliminary safety and efficacy results for ET-01, its investigational gene-editing therapy for transfusion dependent β-thalassemia at the 64th American Society of Hematology Annual Meeting and Exposition on December 10-13, 2022 in New Orleans, Louisiana.

Immunovia will publish its third quarter 2022 results on November 10, 2022 at 8:30 am CET.

Genentech, a member of the Roche Group, announced that it will present new data from its industry-leading hematology portfolio at the 64th American Society of Hematology Annual Meeting from December 10-13, 2022.

Genmab A/S (Nasdaq: GMAB) announced today that 19 abstracts evaluating various investigational medicines in its pipeline have been accepted for presentation at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH), being held at the Ernest N. Morial Convention Center in New Orleans, Louisiana, and virtually, December 10-13.

Ryvu Therapeutics [WSE:RVU] today announced that new data demonstrating clinical and preclinical activity of its selective CDK8/19 inhibitor RVU120 and its selective PIM/FLT3 inhibitor SEL24 (MEN1703) will be presented at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition, which is being held on December 10 –13, 2022, in New Orleans, Louisiana.